new semaglutide regulations fda for alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products These highlights do not include – New 2026 health care laws

Semaglutide treatment begins with a small starting dose of 0.25 mg that increases slowly over several weeks or months

3 Subsequent work extended these findings to people with type 1 and type 2 diabetes, confirming that amylin-receptor agonism measurably slows emptying across populations

Separately, GLP-1 drugs appear to reduce alcohol cravings: a May 2026 Lancet trial found semaglutide cut heavy drinking days by 41% versus 26% on placebo in adults with alcohol use disorder and obesity

If this efficacy holds up in pivotal phase 3 studies, semaglutide will offer a big step forward in effectiveness for obesity treatment

Cardiorenal syndrome revisited